EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 70 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Coping with Grief: An Interview with Author Rebecca Munn September 28, 2020 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... January 27, 2020 EMA Recommends Granting a Marketing Authorisation for Melphalan October 1, 2020 Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer May 25, 2018 Load more HOT NEWS Holiday Coping and Enjoying Prostate Cancer Prevention and Finasteride: A Conversation with NCI’s Dr. Howard... President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions...
